Testolactone
| 180px | |
| Systematic (IUPAC) name | |
|---|---|
|
(4aS,4bR,10aR,10bS,12aS)-10a,12a-dimethyl-3,4,4a,5,6,10a,10b,11,12,12a-decahydro-2H-naphtho[2,1-f]chromene-2,8(4bH)-dione | |
| Clinical data | |
| Pregnancy category |
|
| Routes of administration | Oral |
| Pharmacokinetic data | |
| Protein binding | ~85% |
| Metabolism | Hepatic |
| Excretion | Renal |
| Identifiers | |
| CAS Number | 968-93-4 |
| ATC code | none |
| PubChem | CID 13769 |
| DrugBank | DB00894 |
| Chemical data | |
| Formula | C19H24O3 |
| Molar mass | 300.39 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
| (verify) | |
Testolactone, or Teslac (brand name) is an antineoplastic agent that is a derivative of progesterone and is used to treat advanced stage breast cancer.[1]
It is nonselective.[2]
Pharmacology
Testolactone is a synthetic antineoplastic agent that is structurally distinct from the androgen steroid nucleus in possessing a six-membered lactone ring in place of the usual five-membered carbocyclic D-ring. Despite some similarity to testosterone, testolactone has no in vivo androgenic effect. No other hormonal effects have been reported in clinical studies in patients receiving testolactone.[3]
Mechanism of action
The principal action of testolactone is reported to be inhibition of steroid aromatase activity and the reduction in estrone synthesis that follows. Androstenedione, a 19-carbon steroid hormone produced in the adrenal glands and the gonads, is where estrone synthesis originates and is the source of estrogen in postmenopausal women. In vitro studies report that the aromatase inhibition may be noncompetitive and irreversible, and could possibly account for the persistence of this drug's effect on estrogen synthesis after drug withdrawal.[4]
Uses
This drug is mainly used for treating various types of breast cancer in women who have been through menopause or whose ovaries no longer function.[5] It works by blocking the production of estrogen, which helps prevent the growth of breast cancers that are activated by estrogen. It may also prevent tumor cells from being activated by other hormones.[6]
Side effects
The most common side effects include:
- Abnormal skin sensations
- Aches of the legs and arms
- General body discomfort
- Hair loss
- Loss of appetite
- Nausea
- Redness of the tongue
- Vomiting
References
 | Constructs such as ibid. and loc. cit. are discouraged by Wikipedia's style guide for footnotes, as they are easily broken. Please improve this article by replacing them with named references (quick guide), or an abbreviated title. |
Cite error: Invalid <references> tag;
parameter "group" is allowed only.
<references />, or <references group="..." />
| 40px | This antineoplastic or immunomodulatory drug article is a stub. You can help ssf by expanding it. |
- ↑ Testolactone at DrugBank.ca
- ↑ Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
- ↑ [1] at DrugBank.ca
- ↑ DrugBank: DB00894 (Testolactone)
- ↑ Testolactone facts and comparisons at Drugs.com
- ↑ ibid.
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles needing cleanup from July 2010
- Articles with invalid date parameter in template
- All pages needing cleanup
- 2Fix
- Chemotherapeutic agents
- Steroids
- Lactones
- Naphthochromenes
- Antineoplastic and immunomodulating drug stubs
